Balaji Amines Limited stands as the largest manufacturer of aliphatic amines and their derivatives in India and the sole producer of several specialty chemicals. The company is engaged in the business of manufacture and sale of specialty chemicals, aliphatic amines, and derivatives. Additionally, Balaji Amines runs a five-star hotel in Solapur, Maharashtra, namely Balaji Sarovar Premiere.
The company operates through three segments: Amines & Specialty Chemicals, Hotel Division, and Other segments. Balaji Amines Ltd specializes in manufacturing Methylamines, Ethylamines, Derivatives of specialty chemicals, and Pharma Excipients. These have been the main products, and the company also has facilities for the manufacturing of derivatives, which are downstream products for various pharma/pesticide industries apart from user specific requirements.
The company's amines products include MONOMETHYLAMINE (MMA), DIMETHYLAMINE (DMA), DIETHYLAMINE, and TRIMETHYLAMINE. Its specialty chemicals portfolio comprises N-Methyl Pyrrolidone (NMP), Morpholine, 2-PYRROLIDONE (2-P), N-ETHYL-2-PYRROLIDONE, GAMMA-BUTYROLACTONE, ACETONITRILE (ACN), and DIMETHYLFORMAMIDE (DMF). The derivatives segment includes Di-Methyl Acetamide (DMAC), Di-Ethyl Amine Hydrochloride (DMA HCL), Tri-Ethyl Amine Hydrochloride (TEA HCL), Di-Ethyl Amine Hydrochloride (DEA HCL), and Tri-Methyl Amine Hydrochloride (TMA HCL).
The company primarily focuses on producing methylamines, ethylamines, and derivatives which are essential chemicals used in various industrial applications. These products are widely used in pharmaceuticals, agrochemicals, water treatment, and other chemical industries.
As of July 2025, Balaji Amines Limited has a market capitalization of ₹4,809.93 Crore. The company is a leading ISO 9001:2015 certified manufacturer of Methylamines, Ethylamines, Specialty Chemicals, and Pharma Excipients. Balaji Amines is renowned for its advanced manufacturing and R&D capabilities.
Promoter holding in Balaji Amines Ltd has increased to 54.62% as of March 2025 from 53.70% as of June 2024. The company is almost debt-free. The company maintains a healthy balance sheet with a reasonable debt to equity ratio of 1%.
In the fourth quarter of fiscal year 2025 (Q4 FY25), Balaji Amines Ltd reported a total income of ₹422.69 Crore, representing a significant quarter-over-quarter increase of 31.8% compared to Q3 FY25's ₹320.59 Crore. However, when compared year-over-year to Q4 FY24, which recorded a total income of ₹476.90 Crore, there was a decline of 11.4%.
The company's profitability metrics for Q4 FY25 demonstrated robust performance with a profit before tax (PBT) of ₹92.90 Crore, showing an impressive QoQ growth of 127.2% from ₹40.89 Crore in Q3 FY25. Year-over-year, the PBT increased by 9.3% compared to ₹84.96 Crore in Q4 FY24.
The profit after tax (PAT) stood at ₹72.48 Crore for Q4 FY25, representing a 132.8% increase QoQ from ₹31.14 Crore in Q3 FY25. The YoY increase in PAT was 31.3% from ₹55.21 Crore in Q4 FY24.
- Revenue (Q4 FY25): ₹422.69 Crore
- PAT (Q4 FY25): ₹72.48 Crore
- EPS (Q4 FY25): ₹21.00
- Annual Revenue (FY25): ₹1,458.29 Crore
- Market Cap: ₹4,809.93 Crore
- Dividend (FY25): ₹11 per share
The earnings per share (EPS) for Q4 FY25 was ₹21.00, demonstrating a 105.9% QoQ growth from ₹10.20 and a 43.8% YoY increase from ₹14.60 in Q4 FY24. The Board has recommended a final dividend of ₹11 per share (550% on face value of ₹2) for FY25.
Balaji Amines started commercial production of Isopropylamine on June 30, 2025, targeting the domestic market. This expansion demonstrates the company's continued focus on diversifying its product portfolio and enhancing its manufacturing capabilities.
Looking ahead, the company maintains a positive outlook for long-term opportunities, anticipating growth and increased prospects during FY26. The management has indicated that despite macroeconomic volatility and input cost pressures, the company continues to focus on cost management and high-margin specialty offerings.
The company has delivered a modest sales growth of 8.37% over the past five years. The company shows an annual revenue de-growth of -30% that needs improvement, but maintains a pre-tax margin of 18% and ROE of 11%. The company has demonstrated resilience in maintaining profitability despite challenging market conditions and continues to invest in capacity expansion and product development.
Future growth will hinge on capacity expansion, downstream integration, and export diversification. Founded in 1988, Balaji Amines strives to lead with sustainability, backwards integration, and innovation in the specialty chemicals sector.
